Thursday Top Market Movers ( CYMI, ZHNE, SIFY, ITMN )

Los Angelas, CA -- (SBWIRE) -- 10/18/2012 -- Cymer, Inc. (NasdaqNM:CYMI) is +23.62 - +49.38% from the previous close of $47.83. It traded between $69.64 - 77.29 with total traded volume of 14007794 shares. Keep a close eye on CYMI, as the stock has been showing unusual moves over the past weeks. At Current market price, CYMI has recovered +82.08% from its 52-week Low of 39.24 and has Pulled back -7.56% from its 52-week high of 77.29. Skadden Arps Slate Meagher & Flom LLP is representing ASML Holding NV (ASML), Europe’s largest semiconductor-equipment supplier, which agreed to buy Cymer Inc. (CYMI) for 1.95 billion euros ($2.6 billion), its biggest deal ever, to satisfy customer demand for more advanced chipmaking technology. Sullivan & Cromwell LLP represents Cymer. Skadden attorneys leading this matter include partners Richard Ely and Neil Stronski, M&A; Ian John, antitrust and competition; Neil Leff, executive compensation and benefits; Simon Baxter, European antitrust and competition; Sally Thurston, tax; and James McDonald, corporate finance.

How Should Investors React to CYMI Now? Find Out Here

Zhone Technologie (NCM:ZHNE) is +0.0292 - +5.12% from the previous close of $0.5708. It traded between $0.5695 - 0.62 with total traded volume of 117052 shares. Keep a close eye on ZHNE, as the stock has been showing unusual moves over the past weeks. At Current market price, ZHNE has recovered +20.00% from its 52-week Low of 0.50 and has Pulled back -60.53% from its 52-week high of 1.52. Zhone Technologies, Inc. (NAS:ZHNE) , a global leader in FTTx network access solutions, today reported its financial results for the third quarter ended September 30, 2012. Revenue for the third quarter of 2012 was $29.2 million compared to $30.8 million for the second quarter of 2012 and $30.2 million for the third quarter of 2011. Net loss for the third quarter of 2012, calculated in accordance with generally accepted accounting principles ("GAAP"), was $4.2 million or $0.14 per share compared with a net loss of $2.1 million or $0.07 per share for the second quarter of 2012 and a net loss of $2.7 million or $0.09 per share for the third quarter of 2011. Adjusted earnings before stock-based compensation, interest, taxes, and depreciation ("adjusted EBITDA") was an adjusted EBITDA loss of $3.2 million for the third quarter of 2012, compared to an adjusted EBITDA loss of $1.7 million for the second quarter of 2012 and an adjusted EBITDA loss of $1.3 million for the third quarter of 2011.

Should Investor Buy ZHNE From This Point : To Know More CHECK HERE

Sify Technologies (NasdaqNM:SIFY) is +0.4211 - +18.39% from the previous close of $2.29. It traded between $2.46 - 3.10 with total traded volume of 3594076 shares. Keep a close eye on SIFY, as the stock has been showing unusual moves over the past weeks. At Current market price, SIFY has recovered +42.69% from its 52-week Low of 1.90 and has Pulled back -57.97% from its 52-week high of 6.45. Sify Technologies Limited (ADR)(NASDAQ:SIFY) stock soared 26.53% to $2.90 after the company announced its consolidated results under International Financial Reporting Standards (IFRS) for the second quarter of fiscal year 2012-13. The company posted second quarter revenues of INR 2059 million, as against revenues of INR 1815 million for the corresponding quarter of the previous year, a growth of 13%. Net profit for the quarter was INR 612 million, as against a net loss of INR 89 million in the corresponding quarter previous year.

Don’t Forget To Apply For Trend Analysis Here

InterMune, Inc. (NasdaqNM:ITMN) is +1.30 - +16.31% from the previous close of $7.97. It traded between $8.10 - 9.31 with total traded volume of 4309660 shares. Keep a close eye on ITMN, as the stock has been showing unusual moves over the past weeks. At Current market price, ITMN has recovered +28.57% from its 52-week Low of 7.21 and has Pulled back -65.96% from its 52-week high of 27.23. InterMune, Inc. (Nasdaq: ITMN) - up percent. Reported that on October 16, 2012, the Journal Officiel de la République Française (the official gazette of the French Republic, which serves as the primary source by which the national government of France disseminates legal information about its activities) published the price of Esbriet (pirfenidone). The publication of price in the Journal Officiel is the final step in the reimbursement process for a new medicine in France. As announced by InterMune, Inc. on September 11, 2012, the Comité Economique des Produits de Santé (France’s Economic Committee on Health Care Products) authorized an ex-factory reimbursed price of 1.923,08€ for a four-week treatment pack of Esbriet, corresponding to 25,000€ per patient, per year (approximately $32,000 USD at the then current exchange rates). InterMune expects to commence the commercial launch of Esbriet in France for the treatment of idiopathic pulmonary fibrosis (IPF) in the second half of November 2012.

How Should Investors Trade ITMN Now? Find Out Here

Disclaimer:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com